India, March 7 -- AstraZeneca Pharma India, a science-led biopharmaceutical company, has received a Central Drugs Standard Control Organisation (CDSCO) approval to import for sale and distribution of Durvalumab 120 mg/2.4mL and 500 mg/10 mL solution for infusion.

This approval pertains to a new indication - the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

Durvalumab is now the only approved consolidation therapy for LS-SCLC patients post-CRT, marking a pivotal shift in treatment strategy for this aggressive lung cancer subtype, which constitutes approximately 15% of all lung cancer cases. While most SCLC cases are diagnos...